Intermittent Versus Continuous Feeding in ICU Patients

Status Completed

Clinical Trial Summary

The purpose of this study is to determine whether intermittent nasogastric enteral feeding, rather than conventional continuous enteral feeding, will preserve muscle mass in the critically ill (Primary end-point). Such maintenance may translate into improved outcomes including reduced length of intensive care unit (ICU) and/or hospital stay, as well as number of days on a ventilator. In addition, long-term improvements in health-related quality of life and physical activity levels may result in these ICU survivors once they are back in the community. Indeed, such benefits could translate into reductions in primary healthcare usage and its related costs (secondary end-points).

Clinical Trial Description

This is a Phase II pilot single-blinded randomized controlled trial to be conducted in two adult intensive care units. Technically, the patient will be blinded (by virtue of illness), and in any case knowledge of the feeding intervention they are receiving would not influence outcome. Scans will be taken by staff who could potentially be aware of treatment; keeping scanner personnel blinded would involve complex logistics to separate those randomising, scanning patients, and collecting data; however, the investigators don't think that the individuals taking the scans would introduce material bias. Importantly, all scans will be analysed by the same individual (based off-site) who will be blind to treatment status.

Within 24 hours of admission to ICU, patients recruited to the study will be randomised to either intermittent enteral feeding or continuous enteral feeding - both regimens delivering the same nutritional content over a 24 hour period. The intermittent feeding regimen will consist of six bolus feeds (one bolus every four hours) while the continuous feeding regimen consists of the total volume of feed administered over 24 hours. Feed volume in both groups will commence according to a standard 'usual practice' protocol so as not to delay feeding, but each patient will then have an individual regimen calculated by the dietician. Feeding will continue as either intermittent or continuous for the duration of the trial period as tolerated.

Ultrasound of the thigh (enabling derivation of the Rectus Femoris cross sectional area (RFCSA)) will be performed on Days 1,7,10 (or at discharge, if sooner), and at hospital discharge (if after Day 10), with blood and urine samples taken daily. The hospital discharge destination will be noted, and functional assessment will be determined prior to hospital discharge by two validated methods previously used in this patient cohort (6-Minute Walk Distance and Short Performance Battery Test). Patients' health-related quality of life (HRQOL) will be determined for the pre-morbid period and at 12 months post ICU-discharge using the Short Form-36 health survey; primary care costs since discharge will also be ascertained. ;

Study Design

Related Conditions & MeSH terms

Intensive Care (ICU) Myopathy

Clinical Trial Details

NCT number	NCT02358512
Study type	Interventional
Source	Guy's and St Thomas' NHS Foundation Trust
Contact
Status	Completed
Phase	Phase 2
Start date	February 2015
Completion date	January 2018

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03697785` - Weaning Algorithm for Mechanical VEntilation	N/A
Recruiting	`NCT03810768` - Metabolomics Study on Postoperative Intensive Care Acquired Muscle Weakness
Completed	`NCT03717831` - Muscle Dysfunction in Critical Illness
Recruiting	`NCT05211661` - Diaphragm Atrophy and Dysfunction in Mechanical Ventilation
Completed	`NCT05282576` - Effect of Neurophysiological Facilitation Techniques in Intensive Care Patients	N/A
Completed	`NCT03124342` - Vanderbilt ICU Recovery Program Pilot Trial	N/A
Completed	`NCT03819959` - Metabolomics Study on Intensive Care Acquired Muscle Weakness in Polytrauma
Active, not recruiting	`NCT02685215` - Prognostic Factors , Morbidity and Mortality in Patients With Neuromuscular Disorders Admitted in ICU
Completed	`NCT01372176` - Early Goal-Directed Nutrition in ICU Patients - EAT-ICU Trial	Phase 4
Completed	`NCT03619915` - Correlation Between Spirometry and Functional Independence in Adult Post-ICU Patients
Completed	`NCT01364714` - Biomechanical Properties in Intensive Care Unit (ICU) Survivors 12-month After Discharge	N/A
Completed	`NCT03714399` - Muscle Recovery Following Aortic Surgery Induced ICUAW.
Active, not recruiting	`NCT03936920` - Intra and Inter Reliability and Validity of the Turkish Version of Ottowa Sitting Scale in Intensive Care Unit Survivors
Completed	`NCT02911896` - Physical Function in Critical Care (PaciFIC)	N/A
Terminated	`NCT01633593` - Treatment of Delirium in the Elderly With Donepezil: a Double-blind, Randomized, Placebo-controlled Clinical Trial	Phase 4
Completed	`NCT03547687` - Neurosciences-Intensive Care Unit Electrical Stimulation	N/A
Recruiting	`NCT03753412` - Recovery From ICUAW Following Severe Respiratory and Cardiac Failure

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.